Wednesday, April 1, 2020
Breaking Medical Device Industry News
Home Abbott

Abbott

Next-Generation Heart Rhythm Management Devices in Europe, Featuring State-of-the-Art Patient App and Bluetooth Connectivity

Abbot reports the devices offer new opportunities for patient engagement and remote monitoring through new smartphone connectivity and connected applications. Additional benefits include a patient preferred design, improved battery longevity, and MRI compatibility.

Tendyne™ Transcatheter Mitral Valve Implantation System Receives CE Mark

This life-changing therapy treats significant mitral regurgitation in patients requiring a heart valve replacement and provides a safe and effective solution for MR patients who are not candidates for open-heart surgery or transcatheter mitral valve repair.

Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson’s Disease

With this approval, Abbott's Infinity DBS is now the only directional DBS system approved for all major targets used to treat movement disorders, Parkinson's disease and Essential Tremor: the subthalamic nucleus (STN), ventral intermediate nucleus (VIM) and GPi. 

Abbott’s High Sensitivity Troponin-I Blood Test Receives FDA Approval

As one of the most researched troponin diagnostic tests, doctors in the U.S. can now utilize this proven technology to help detect heart attacks faster and more accurately than contemporary troponin tests.

Abbott’s HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant

10/19/18: With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives.

New Study: Abbott’s Novel Diagnostic Test Has the Potential to Demonstrate Gold Standard Accuracy and Speed

10/17/18: New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient's side in as little as 15 minutes could identify nearly three-fifths (56.7 percent) of people at low-risk of experiencing a heart attack, similar to the results of a High Sensitive Troponin-I blood test done in the laboratory setting.

Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling

8/2/18: Parkinson's disease and essential tremor patients can now benefit from upgraded functionality with Abbott's Infinity™ DBS system.

Five-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting Decisions

5/22/18: "For the first time, a study has shown that patients with stable coronary artery disease who received a stent guided by an FFR diagnostic had a benefit over medical therapy alone, including fewer heart attacks and needs for urgent revascularization," said principal investigator Bernard De Bruyne, M.D., Ph.D., of the Cardiovascular Center Aalst, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium. "Data from this study confirm the importance of FFR-guided stenting decisions combined with medical therapy over medical therapy alone."